India BSE NSE Trading Suspension Orders — October 23, 2026

Consolidated revenue from operations rose to ₹5,290 Lakhs from ₹4,712 Lakhs (about 12% YoY), indicating underlying top-line growth despite the earnings noise

The SEBI promoter dealing restriction (2 years, ordered 5 Feb 2026) was stayed by SAT on 7 May 2026, lowering near-term regulatory constraint on promoter activity pending the November 2026 hearing

Deconsolidation of Dr. Smith removes a business with negative net worth of ₹(987.00) lakh and NIL revenue, with no consideration receivable, so the exit is a clean write-off of a loss-making holding rather than a cash outflow

Standalone revenue from operations fell to ₹29 Lakhs from ₹38 Lakhs YoY, showing the parent entity has negligible operating activity and value rests on investments

Continuing-operations loss widened to ₹661 Lakhs in Q1 FY27 from ₹411 Lakhs in Q1 FY26 (about 61% deterioration), so the reported profit of ₹20,332 Lakhs overstates underlying performance

Dr. Smith contributed only ₹1.03 lakh of consolidated FY 2025-26 total income of ₹2,946.87 lakh, so the operational impact of the exit on reported revenue is immaterial

Auditors issued a qualified review conclusion because two subsidiaries and two step-down subsidiaries (revenue ₹3,411 Lakhs, PAT ₹547 Lakhs, assets ₹11,987 Lakhs) were unreviewed and reviewed asset coverage fell below the 80% Regulation 33(3)(h) threshold

Auditors flagged a going-concern uncertainty at subsidiary Lava Cast Private Limited, a warning sign for group-level financial stability

Consolidated profit after tax of ₹20,332 Lakhs was driven by the one-time SASPL divestment gain, while continuing operations posted a loss, so headline profitability is non-recurring

SEBI QJA order restrains promoter directors from dealing in securities for 2 years; the stay is provisional and the matter returns to SAT in November 2026, leaving an unresolved enforcement overhang

Deconsolidation of Dr. Smith reduces consolidated net worth from ₹853.60 lakh by 115.63% effectively to a deficit-adjusted base, indicating material balance sheet impairment from the subsidiary's insolvency

The subsidiary was taken into CIRP via a Section 7 SIDBI petition admitted April 28, 2025, signaling prior creditor stress that may recur in other group entities

Standalone PBT of ₹20,530 Lakhs is almost entirely a ₹21,428 Lakhs investment gain against ₹29 Lakhs revenue, so the parent's earnings are highly sensitive to lumpy divestment outcomes

Exiting a subsidiary with negative net worth of ₹(987.00) lakh and NIL revenue removes a drag on future group losses, potentially improving forward return profile once the write-off is absorbed

Resolving the going-concern issue at Lava Cast would remove a principal contingent liability and could unlock value in the remaining subsidiary portfolio

Consolidated revenue growth of about 12% YoY suggests the operating businesses retained after the SASPL divestment are expanding, a potential re-rating catalyst if margins recover

A favorable SAT ruling at the November 2026 hearing would fully remove the promoter-dealing restriction, reducing governance discount and widening the investor base

Bringing the two unreviewed subsidiaries and two step-downs into review scope and restoring 80%+ asset coverage would clear the qualified conclusion and improve disclosure credibility

The Ananta Medicare resolution plan shows the IBC process can conclude with a defined outcome, giving clarity on the group's exposure after a prolonged SIDBI-initiated insolvency

Both filings show headline results distorted by one-time items (Setco's ₹21,428 Lakhs investment gain; Cian's deconsolidation write-off), so reported profit is an unreliable guide to run-rate earnings in this stream

Setco's qualified review conclusion, going-concern flag, and SEBI promoter restriction contrast with Cian's clean regulatory-compliant deconsolidation under Regulation 30, suggesting disclosure rigor varies sharply across listed Indian small caps

Cian's exit via NCLT-approved resolution with equity extinguished illustrates how Section 7 IBC proceedings initiated by lenders such as SIDBI can wipe out subsidiary equity and cut consolidated net worth materially

Setco's exposure to loss-making subsidiaries (Lava Cast going-concern; unreviewed step-downs) and Cian's negative-net-worth subsidiary highlight that consolidated balance sheets can mask weak group entities, warranting subsidiary-level diligence

Promoter dealing restriction stayed; next hearing November 2026 will determine whether the 2-year SEBI order is upheld [Nov 2026]

Watch for expansion of review coverage to unreviewed subsidiaries and restoration of 80% asset threshold to clear qualified conclusion in upcoming quarterly filings

Monitor whether the going-concern uncertainty at Lava Cast is resolved or escalates in subsequent disclosures

Track whether the continuing-operations loss (₹661 Lakhs in Q1 FY27 vs ₹411 Lakhs in Q1 FY26) narrows in the next quarter as the SASPL divestment fully rolls off

Watch for management commentary on remaining group entities and any further subsidiary exposure to IBC proceedings

Monitor rebuild of consolidated net worth from the post-write-off base of ₹853.60 lakh reduction over subsequent quarters